CHRS
CHRS
NASDAQ · Biotechnology

Coherus Oncology Inc

$1.76
+0.07 (+4.14%)
As of Apr 1, 2:20 PM ET ·
Financial Highlights (FY 2025)
Revenue
50.41M
Net Income
-12,744,166
Gross Margin
57.2%
Profit Margin
-25.3%
Rev Growth
-0.9%
D/E Ratio
0.67
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 57.2% 57.2% 57.2%
Operating Margin -21.6% -23.8% -20.0%
Profit Margin -25.3% -24.2% -22.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 50.41M 45.49M 44.34M
Gross Profit 28.81M 26.00M 25.35M
Operating Income -10,863,372 -10,840,195 -8,888,953
Net Income -12,744,166 -11,017,037 -10,122,519
Gross Margin 57.2% 57.2% 57.2%
Operating Margin -21.6% -23.8% -20.0%
Profit Margin -25.3% -24.2% -22.8%
Rev Growth -0.9% +9.2% +11.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 52.08M 52.40M 52.30M
Total Equity 77.23M 72.90M 71.12M
D/E Ratio 0.67 0.72 0.74
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -16,231,640 -13,211,435 -14,610,213
Free Cash Flow -10,845,649 -11,236,120 -8,740,023